Algorae Pharmaceuticals Ltd Clarifies NSW Health Supply Panel Terms [VIDEO]
Algorae Pharmaceuticals (ASX: 1AI) has clarified the terms of its Algorae Pharmaceuticals NSW Health contract, confirming AlgoraeRx as an approved supplier under a standing offer arrangement with first supply expected in Q4 2026 — here's what investors need to know.
Key Takeaways
- AlgoraeRx has been confirmed as an approved supplier under a NSW Health standing offer arrangement, with the counterparty being the Health Administration Corporation and procurement administered by HealthShare NSW.
- The arrangement carries no minimum volume or spend commitment, and Algorae does not expect it to have a material revenue impact in the current calendar year — actual orders will drive any financial outcome.
- First supply under purchase orders is expected in Q4 2026, with onboarding already underway and no conditions precedent to the rollout.
- The term structure is 3+1+1 years, giving AlgoraeRx up to five years of approved supplier status within one of Australia's largest public healthcare procurement networks.
- Investors should watch Algorae's quarterly cash flow reports as the primary indicator of whether purchase orders are being received under the arrangement.
![Genetic Signatures Ltd Gets BCAL Backing Through 10.2% Stake Purchase [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fb377bf6c-56e4-43e5-9dd1-8e08cd86e8c82Fimage_0.jpg)
![Imugene Ltd Reports Second Complete Response in BTKi Cohort [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2F352176a6-56e8-4d9b-a769-8060d34f35502Fimage_0.jpg)
![Algorae Pharmaceuticals Ltd Wins NSW Health Public Hospital Supply Contract [VIDEO]](https://media.stockwirex.com/veo32Fnanobanana2Fbc5a1876-b4d2-41c9-ba61-5ceb353457682Fimage_0.jpg)
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.